Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Merus N.V. - Common Shares (OQ:MRUS)

Business Focus: N/A

Mar 06, 2024 08:00 am ET
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
Gilead Sciences, Inc. (Nasdaq:GILD) and Merus N.V. (Nasdaq:MRUS) today announced a research collaboration, option and license agreement to discover novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. Gilead and Merus agreed to collaborate on the use of Merus’ proprietary Triclonics® platform along with Gilead’s oncology expertise to research and develop multiple, separate preclinical research programs.
Mar 05, 2024 04:30 pm ET
Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression
Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of an abstract highlighting the...
Mar 04, 2024 08:00 am ET
Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will...
Feb 28, 2024 04:15 pm ET
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the fourth quarter and...
Jan 31, 2024 08:00 am ET
Merus to Participate in Upcoming Investor Conferences
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will...
Dec 02, 2023 08:40 pm ET
Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023
Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced updated interim clinical data on...
Nov 26, 2023 11:05 am ET
Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023
Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of two abstracts regarding...
Nov 02, 2023 04:12 pm ET
Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update
Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the third quarter and...
Nov 01, 2023 08:00 am ET
Merus to Participate in Upcoming Investor Conferences
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will...
Oct 23, 2023 07:30 am ET
Merus’ Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer
Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced interim clinical data, as of a July 31,...
Oct 15, 2023 07:58 pm ET
Merus Announces Business Update Conference Call
Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that it will host a conference call to discuss a...
Oct 13, 2023 09:00 am ET
Oct 06, 2023 09:32 am ET
Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023
Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the acceptance of abstracts on the bispecific...
Aug 31, 2023 08:00 am ET
Merus to Participate in Upcoming Investor Conferences
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will...
Aug 09, 2023 09:53 pm ET
Merus Announces Pricing of Public Offering of Common Shares
Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the pricing of an underwritten public...
Aug 09, 2023 04:01 pm ET
Merus N.V. Announces Proposed Public Offering of Common Shares
Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the launch of a proposed underwritten...
Aug 07, 2023 04:26 pm ET
Merus Announces Financial Results for the Second Quarter 2023 and Provides Business Update
Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the second quarter and...
Jul 28, 2023 08:00 am ET
Merus Announces Two Clinical Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) non-small cell lung cancer (NSCLC) and Pancreatic Cancer (PDAC) Selected for Presentation at the ESMO Congress 202
Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced two abstracts were selected for presentation at...
Jul 05, 2023 04:01 pm ET
Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug Administration
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®) for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted...
Jun 29, 2023 04:30 pm ET
Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancer
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®) for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted...
Jun 15, 2023 07:47 am ET
Merus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial Officer
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Greg Perry as the Company’s Chief Financial Officer (CFO)....
May 31, 2023 08:00 am ET
Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference 2023
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will...
May 04, 2023 04:25 pm ET
Merus Announces Financial Results for the First Quarter 2023 and Provides Business Update
Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the first quarter and...
Apr 17, 2023 10:15 am ET
Merus’ Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma (HNSCC)
Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced interim clinical data as of a February...
Apr 14, 2023 11:10 am ET
Merus Announces Publication of an Abstract on Petosemtamab in Advanced Gastric/Esophageal Adenocarcinoma for Presentation at the AACR Annual Meeting 2023
Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of an abstract for a poster...
Apr 14, 2023 11:10 am ET
Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2023
Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of an abstract for a plenary...
Mar 14, 2023 04:30 pm ET
Merus Announces Petosemtamab in Previously Treated Head and Neck Squamous Cell Carcinoma Abstract Selected for Plenary Session Oral Presentation at the AACR Annual Meeting 2023
Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the selection of an abstract for a plenary...
Mar 14, 2023 04:30 pm ET
Merus Announces Publication of an Abstract on Preclinical Mechanism of Action of MCLA-129 Selected for Poster Presentation at the AACR Annual Meeting 2023
Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of an abstract highlighting the...
Feb 28, 2023 04:25 pm ET
Merus Announces Financial Results for the Fourth Quarter and Full Year 2022 and Provides Business Update
Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the fourth quarter and...
Feb 01, 2023 08:00 am ET
Merus to Participate in Upcoming Investor Conferences
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will...
Jan 09, 2023 06:05 am ET
CORRECTING and REPLACING --Merus Provides 2023 Outlook
Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today provided its 2023 outlook. “2023 looks to be...
Jan 08, 2023 09:00 am ET
Merus Provides 2023 Outlook
Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today provided its 2023 outlook. “2023 looks to be...
Nov 09, 2022 08:00 am ET
Merus to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will...
Nov 03, 2022 07:51 am ET
Merus Announces Financial Results for the Third Quarter and Provides Business Update
Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the third quarter...
Oct 26, 2022 04:00 am ET
Merus Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of interim data as of an...
Oct 12, 2022 07:00 am ET
Merus Announces Publication of Abstract on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of the abstract...
Sep 07, 2022 04:10 pm ET
Merus Announces Poster Presentation on MCLA-129 at the 34th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics
Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the selection of an abstract for a...
Sep 01, 2022 08:00 am ET
Merus to Participate in a Panel Discussion at Citi's 17th Annual BioPharma Conference
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will...
Aug 08, 2022 04:17 pm ET
Merus Announces Financial Results for the Second Quarter and Provides Business Update
Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the second quarter...
Jun 05, 2022 11:00 am ET
Merus Presents Clinical Data on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Oral Abstract)
Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced interim efficacy data as of an April 12,...
Jun 03, 2022 08:00 am ET
Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will...
May 26, 2022 05:00 pm ET
Merus Announces Publication of Abstract of Zenocutuzumab in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of the abstract...
May 17, 2022 08:00 am ET
Merus to Present at the H.C. Wainwright Global Investment Conference
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will...
May 09, 2022 04:29 pm ET
Merus Announces Financial Results for the First Quarter 2022 and Provides Business Update
Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the first quarter...
Apr 27, 2022 04:01 pm ET
Zenocutuzumab Clinical Abstract Selected for Oral Presentation at the 2022 American Society of Clinical Oncology Annual Meeting
Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the selection of an abstract for oral...
Apr 25, 2022 08:00 am ET
Merus Announces Publication in Nature Cancer on Petosemtamab’s (MCLA-158) Unique Mechanism of Action
Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced publication of a preclinical report on...
Apr 08, 2022 01:00 pm ET
Merus Presents Preclinical Data on MCLA-129 at the American Association for Cancer Research Annual Meeting 2022
Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today released pre-clinical data highlighting the...
Apr 06, 2022 08:00 am ET
Merus to Participate in a Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will...
Mar 08, 2022 04:35 pm ET
Merus Announces Publication of Abstract on MCLA-129 at the American Association for Cancer Research 2022 Annual Meeting
Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of the abstract...
Feb 28, 2022 04:36 pm ET
Merus Announces Financial Results for the Fourth Quarter and Full Year 2021 and Provides Business Update
Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the fourth quarter and full year...
Feb 03, 2022 08:00 am ET
Merus to Participate in Upcoming Investor Conferences
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will...
Jan 25, 2022 04:30 pm ET
Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145
Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Shannon Campbell as...
Dec 10, 2021 08:00 am ET
Merus Presents Updated Analysis of Zenocutuzumab, Trastuzumab, and Vinorelbine in Patients with HER2+ Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium
Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), presented clinical data on zenocutuzumab (Zeno) in...
Dec 06, 2021 06:42 am ET
Merus Presents Clinical Data on MCLA-145 at the ESMO Immuno-Oncology Congress 2021
Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today released clinical data on MCLA-145 from the phase...
Dec 02, 2021 08:00 am ET
Merus Announces Poster Presentation on Clinical Data on MCLA-145 at the ESMO Immuno-Oncology Congress 2021
Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of the abstract...
Nov 10, 2021 08:00 am ET
Merus to Participate in a Fireside Chat at the Jefferies London Healthcare Conference (Virtual)
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a...
Nov 04, 2021 09:01 pm ET
Merus Announces Pricing of Public Offering of Common Shares
Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced the pricing of an underwritten public...
Nov 04, 2021 04:07 pm ET
Merus N.V. Announces Proposed Public Offering of Common Shares
Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the launch of a proposed underwritten...
Nov 02, 2021 04:20 pm ET
Merus Announces Regulatory Update on Zenocutuzumab, Financial Results for the Third Quarter and Provides Business Update
Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced a regulatory update for the...
Oct 07, 2021 09:00 am ET
Merus Presents Early Clinical Data on MCLA-158 and Preclinical Data on Zenocutuzumab at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today presented clinical data on MCLA-158, including...
Sep 30, 2021 04:35 pm ET
Merus Announces Poster Presentations on Zenocutuzumab and MCLA-158 at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of the abstract titles...
Sep 07, 2021 08:00 am ET
Merus to Participate in Upcoming Investor Conferences
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in...
Aug 05, 2021 05:00 pm ET
Merus Announces Financial Results for the Second Quarter and Provides Business Update
Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the second quarter...
Jul 21, 2021 08:00 am ET
Merus Announces Publication in Nature Communications on MCLA-145’s Novel Mechanism of Action Promoting Tumor Immunity and Context Dependent T-Cell Costimulation
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the novel mechanism of action (MOA) of MCLA-145, the Company’s clinical stage...
Jul 07, 2021 04:20 pm ET
Merus to Participate in William Blair's Biotech Focus Conference 2021
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a...
Jun 04, 2021 12:00 pm ET
Merus Presents Clinical Data on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting (Oral Abstract)
Zenocutuzumab continues to be well tolerated with a favorable safety profile-   Company to host investor call to discuss interim clinical results and provide a program update on Sunday, June 6 at 6:00 PM ET UTRECHT, The Netherlands and CAMBRIDGE,...
May 26, 2021 04:01 pm ET
Merus to Participate in a Fireside Chat at the Jefferies Virtual Healthcare Conference
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a...
May 19, 2021 05:01 pm ET
Merus Announces Publication of Abstract on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
Zenocutuzumab observed to be well tolerated with most adverse events being mild or moderate (Grade 1 or 2)-   Oral presentation of an updated interim analysis of 45 evaluable patients to be presented at ASCO on June 4, 11 AM-2 PM ET-   Company to...
May 13, 2021 08:00 am ET
Merus Announces Collaborations in Israel, Italy and Spain to Increase Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the Phase 1/2 eNRGy Clinical Tri
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced new collaborations in Israel, Italy and Spain to expand molecular screening...
May 11, 2021 08:00 am ET
Merus to Participate in a Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a...
May 06, 2021 05:14 pm ET
Merus Announces Financial Results for the First Quarter and Provides Business Update
Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the first quarter...
May 03, 2021 04:01 pm ET
Merus Announces First Patient Treated in Phase 1/2 Clinical Trial of MCLA-129 in Advanced Lung Cancer and Other Solid Tumors
Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the first patient has been treated...
Apr 28, 2021 04:01 pm ET
Zenocutuzumab Clinical Data Selected for Oral Presentation at the 2021 American Society of Clinical Oncology Annual Meeting
Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the company’s selection for oral...
Mar 16, 2021 04:57 pm ET
Merus Announces Financial Results for the Fourth Quarter and Full Year 2020 and Provides Business Update
Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the fourth quarter and full year...
Mar 10, 2021 04:45 pm ET
Merus Announces Poster Presentations for Zenocutuzumab and MCLA-129 at the American Association for Cancer Research 2021 Annual Meeting
Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Merus will present preclinical data...
Mar 08, 2021 08:00 am ET
Merus to Participate in a Fireside Chat at the 33rd Annual Roth Conference
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., Chief Executive Officer, will participate in a fireside...
Feb 01, 2021 08:00 am ET
Merus to Participate in Upcoming Investor Conferences
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced that Bill Lundberg, M.D., Chief Executive Officer, will participate in the...
Jan 21, 2021 08:40 am ET
Merus Announces Pricing of Public Offering of Common Shares
Merus N.V. (Nasdaq: MRUS) (“Merus”, “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced the pricing of an underwritten public offering of...
Jan 19, 2021 04:18 pm ET
Merus N.V. Announces Proposed Public Offering of Common Shares
Merus N.V. (Nasdaq: MRUS) (“Merus”, “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced the launch of a proposed underwritten public offering...
Jan 19, 2021 05:30 am ET
Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
INDIANAPOLIS and UTRECHT, The Netherlands, Jan. 19, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS), a clinical-stage oncology company developing multi-specific antibodies, today announced a research collaboration and exclusive license agreement that will leverage Merus' proprietary Biclonics® platform along with the scientific and rational drug design expertise of Loxo Oncology at Lilly to research and develop up to three CD3-engaging T-cell re-directing bispecific antibody therapies.
Jan 12, 2021 04:01 pm ET
Merus Announces Collaborations with Nationwide Medical Organizations in the Netherlands and Japan to Enhance Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awaren
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced collaborations with nationwide medical organizations in the Netherlands and Japan...
Jan 11, 2021 05:10 pm ET
Merus Announces Presentation of Phase 1 Clinical Data for MCLA-158 at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium
Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced that clinical data from its Phase 1 dose...
Jan 07, 2021 04:05 pm ET
Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™) for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast...
Dec 17, 2020 08:00 am ET
Merus and Sema4 Enter Into an Agreement to Support Merus’ Phase 1/2 Clinical Trial of Zenocutuzumab
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multi-specific antibodies (Biclonics® and TriclonicsTM), and Sema4, a patient-centered health intelligence company, today announced they have entered...
Nov 16, 2020 08:00 am ET
Merus to Present at the Jefferies Virtual London Healthcare Conference
Merus N.V. (Nasdaq:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced that Bill Lundberg, M.D., President and Chief Executive Officer, will participate...
Nov 09, 2020 08:00 am ET
Merus Announces Poster Presentations on MCLA-145 at Society for Immunotherapy of Cancer
Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced that preclinical data from its MCLA-145...
Nov 05, 2020 04:10 pm ET
Merus Announces Financial Results for the Third Quarter and Provides Business Update
Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and TriclonicsTM), today announced financial results for the third quarter...
Oct 12, 2020 05:00 pm ET
Merus and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clinical Trial Awareness for Cancer Patients with Neuregulin 1 Fusion Tumors
myTomorrows, a global health technology company, and Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced the expansion of their...
Aug 07, 2020 08:30 am ET
Merus to Present at the 2020 Wedbush PacGrow Healthcare Conference
Merus N.V. (Nasdaq:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced that Bill Lundberg, M.D., President and Chief Executive Officer, will present a...
Aug 06, 2020 04:07 pm ET
Merus Announces Financial Results for the Second Quarter and Provides Business Update
Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and TriclonicsTM), today announced financial results for the second...
Jul 27, 2020 08:00 am ET
Merus announces FDA Orphan Drug Designation of Zenocutuzumab for the Treatment of Pancreatic Cancer
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™) for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan...
Jul 27, 2020 08:00 am ET
Merus Appoints Andrew Joe, M.D., as Chief Medical Officer
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced the appointment of Andrew Joe, M.D., as Chief Medical Officer. Dr. Joe is a...
Jul 13, 2020 04:01 pm ET
Merus and Caris Life Sciences Announce Collaboration to Detect NRG1 Fusions in Cancer Patients
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™) and Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the...
Jun 01, 2020 04:05 pm ET
Merus to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced that Bill Lundberg, M.D., Chief...
May 14, 2020 09:05 am ET
Merus Announces the Acceptance of Six Abstracts at Upcoming Medical Conferences and Provides Program Updates
Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced the acceptance of six abstracts at...
May 11, 2020 04:36 pm ET
Merus Announces Financial Results for the First Quarter and Provides Business Update
Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and TriclonicsTM), today announced financial results for the first quarter...
Mar 12, 2020 04:01 pm ET
Merus Announces Financial Results for the Fourth Quarter and Full Year 2019 and Provides Business Update
Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and TriclonicsTM), today announced financial results for the fourth quarter and full year...
Dec 16, 2019 08:30 am ET
Merus Announces Chief Executive Officer Transition
Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage company developing innovative, full-length bispecific antibodies (Biclonics®), today announced that Dr. Ton Logtenberg will step down as CEO, President, Principal...
Nov 12, 2019 04:01 pm ET
Merus Announces Financial Results for the Third Quarter 2019 and Provides Business Update
Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage company developing innovative, full-length bispecific antibodies (Biclonics®), today announced financial results for the third quarter ended September 30, 2019 and...
Nov 05, 2019 08:32 am ET
Merus Announces Pricing of Public Offering of Common Shares
Merus N.V. (Nasdaq: MRUS), a clinical-stage bispecific antibody company developing Biclonics®, today announced the pricing of an underwritten public offering of 4,750,000 common shares, at a public offering price of $14.50 per share, before...
Nov 04, 2019 04:54 pm ET
Merus N.V. Announces Proposed Underwritten Public Offering of Common Shares
Merus N.V. (Nasdaq: MRUS), a clinical-stage bispecific antibody company developing Biclonics®, today announced the launch of a proposed underwritten public offering of up to $60.0 million of its common shares. All of the common shares are being...
Oct 27, 2019 11:50 am ET
Merus Bispecific Antibody MCLA-128 Shows Encouraging Early Clinical Activity in Patients with Cancers Harboring NRG1 Gene Fusions
Merus N.V. (Nasdaq: MRUS), a clinical-stage company developing innovative, full-length bispecific antibodies (Biclonics®), today announced initial clinical data for three patients with cancers harboring NRG1 fusions treated with MCLA-128 through an...
Oct 25, 2019 11:05 am ET
Merus Announces Presentation and Poster on MCLA-128 and MCLA-129 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage bispecific antibody company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that data from its MCLA-128 and...
Aug 19, 2019 04:01 pm ET
Merus Announces Financial Results for the Second Quarter 2019 and Provides Business Update
Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced financial results for the second...
Jun 03, 2019 08:28 am ET
Merus to Present at the Jefferies 2019 Healthcare Conference
Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., President,...
May 30, 2019 04:05 pm ET
Merus Announces Financial Results for the First Quarter 2019 and Provides Business Update
Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced financial results for the first...
May 23, 2019 08:00 am ET
Merus Announces 2019 Annual General Meeting of Shareholders
Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that the 2019 Annual General Meeting...
May 20, 2019 08:38 am ET
Merus to Present at the RBC Capital Markets 2019 Healthcare Conference
Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., President,...
May 09, 2019 08:00 am ET
Merus Announces First Patient Treated in Phase 1 Clinical Trial of MCLA-145 for Advanced Solid Tumors
Merus N.V. (Nasdaq: MRUS), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that the first patient has been treated in its Phase 1 trial evaluating...
Apr 03, 2019 04:00 pm ET
Merus Announces Financial Results for the Full Year 2018 and Provides Business Update
Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced financial results for the full year...
Apr 01, 2019 07:00 am ET
Merus and Incyte Present MCLA-145 Program Preclinical Data at the AACR Annual Meeting 2019
Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, and in collaboration with Incyte (Nasdaq: INCY),...
Mar 11, 2019 08:09 am ET
Merus to Present at the Cowen & Co. 39th Annual Health Care Conference
Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief...
Feb 07, 2019 07:00 am ET
Merus to Participate in Guggenheim Healthcare Talks Idea Forum
Merus N.V. (Nasdaq: MRUS), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that Mark Throsby, Ph.D., Executive Vice President and Chief Scientific...
Jan 07, 2019 07:00 am ET
Merus Announces IND Clearance for MCLA-145
Merus N.V. (Nasdaq: MRUS), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced the U.S. Food and Drug Administration (FDA) has accepted the Investigational...
Jan 02, 2019 08:00 am ET
Merus Announces Strategic Collaboration with Betta Pharmaceuticals to Develop and Commercialize MCLA-129 in China
Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that it has agreed to grant Betta...
Dec 27, 2018 05:05 pm ET
Merus Announces Financial Results for the Third Quarter 2018 and Provides Business Update
Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced financial results for the third...
Dec 20, 2018 04:45 pm ET
Merus Announces Global Settlement and End to All Patent Litigation with Regeneron Pharmaceuticals
Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced a settlement of all pending patent litigation and administrative proceedings between Merus and...
Nov 08, 2018 07:00 am ET
Merus to Present at the Jefferies 2018 London Healthcare Conference
Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ton Logtenberg, Ph.D., President and Chief Executive Officer of Merus, will present a...
Oct 19, 2018 09:20 am ET
Report: Developing Opportunities within Spotify Technology SA, Vornado Realty Trust, Merus N.V, Teekay Tankers, PagSeguro Digital, and Liberty Oilfield Services — Future Expectations, Projections Movi
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Spotify Technology SA (NYSE:SPOT), Vornado Realty Trust (NYSE:VNO),...
Sep 27, 2018 04:00 pm ET
Merus to Present at the Cantor Fitzgerald Global Healthcare Conference
Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Hui Liu, Ph.D., Executive Vice President, Chief Business Officer and Head of Merus U.S.,...
Sep 27, 2018 07:00 am ET
Merus Strengthens Team with Key Appointments
Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced updates to its management team. Hui Liu, Ph.D., Executive Vice President and Chief Business...
Aug 30, 2018 07:00 am ET
Merus to Participate in Citi’s 13th Annual Biotech Conference
Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ton Logtenberg, Ph.D., President and Chief Executive Officer, will participate in a panel...
Aug 22, 2018 07:00 am ET
Merus Announces Formation of a Scientific Advisory Board
Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced the formation of a Scientific Advisory Board (SAB), consisting of several world-renowned...
Aug 21, 2018 07:45 am ET
Recent Analysis Shows DURECT, Corporacion America Airports S.A., Golden Star Resources, MacroGenics, Merus N.V., and Superior Uniform Group Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of DURECT Corporation (NASDAQ:DRRX), Corporacion America Airports S.A....
Aug 10, 2018 08:35 am ET
Merus Announces Financial Results for the Second Quarter 2018 & Mid-year Operating Results
Merus N.V. (Nasdaq:MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced financial results for the second quarter ended June 30,...
Aug 07, 2018 07:00 am ET
Merus to Present at the 2018 Wedbush PacGrow Healthcare Conference
Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Hui Liu, Ph.D., Executive Vice President and Chief Business Officer, will present a company...
Jul 26, 2018 07:00 am ET
Merus Announces Recent Corporate Developments and Financial Results for the First Quarter 2018
Merus N.V. (Nasdaq:MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced financial results for the first quarter ended March 31,...
Jul 05, 2018 04:00 am ET
Merus Announces Annual Meeting of Shareholders
Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the Annual General Meeting of Shareholders will be held on Friday, July 20, 2018 at 8:00...
Jun 06, 2018 08:20 am ET
Analysis: Positioning to Benefit within China Biologic Products, Merus N.V, Adient, G1 Therapeutics, Westport Fuel, and AppFolio — Research Highlights Growth, Revenue, and Consolidated Results
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of China Biologic Products, Inc. (NASDAQ:CBPO), Merus N.V. (NASDAQ:MRUS),...
May 31, 2018 07:00 am ET
Merus to Present at the Jefferies 2018 Healthcare Conference
Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Hui Liu, Ph.D., Executive Vice President and Chief Business Officer, will present a company...
May 24, 2018 07:00 am ET
Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors
Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the first patient has been dosed in a Phase 1, first-in human clinical trial of MCLA-158 in...
May 15, 2018 07:00 am ET
Merus Announces Unique Mechanism of Action of MCLA-128 That Potently Blocks HER3 Signaling Published in Cancer Cell
Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced the unique mechanism of action (MOA) of MCLA-128, the Company’s most-advanced Biclonics®...
Apr 26, 2018 07:00 am ET
Merus Announces Recent Corporate Developments and Financial Results for the Fourth Quarter and Full Year 2017
- Phase 2 combination trial in two metastatic breast cancer (MBC) populations initiated for Merus’ most advanced bispecific antibody candidate, MCLA-128 -
Apr 19, 2018 07:00 am ET
Merus to Report Full Year 2017 Financial Results and Corporate Developments on April 26, 2018
Conference call scheduled for Thursday, April 26, 2018, at 8:30 a.m. ET
Apr 09, 2018 08:20 am ET
Analysis: Positioning to Benefit within HudBay Minerals, IRHYTHM TECH, TechTarget, Mercury, Merus N.V, and Tecnoglass — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, April 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of HudBay Minerals Inc (NYSE:HBM), IRHYTHM TECH...
Mar 20, 2018 07:00 am ET
Merus and the Vall d’Hebron Institute of Oncology Announce Research Collaboration to Develop Innovative Bispecific Antibodies for Therapeutic Applications in the Treatment of Cancer
UTRECHT, The Netherlands, March 20, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), and the Vall d’Hebron Institute of Oncology (VHIO), a leading comprehensive cancer center of excellence located...
Mar 16, 2018 07:45 am ET
Report: Exploring Fundamental Drivers Behind Gladstone Commercial, IRHYTHM TECH, Jounce Therapeutics, CoStar Group, Tecnoglass, and Merus N.V — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, March 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Gladstone Commercial Corporation (NASDAQ:GOOD), IRHYTHM TECH...
Mar 14, 2018 07:00 am ET
Merus Announces Ono Pharmaceuticals Exercise of its Option for New Research and License Agreement to Generate Bispecific Antibody Targeting Autoimmune Diseases
UTRECHT, The Netherlands, March 14, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ono Pharmaceutical Co., LTD. (Osaka, Japan, ‘Ono’) has exercised its option under an agreement executed...
Mar 13, 2018 07:00 am ET
Merus’ Intellectual Property Portfolio Expands with Two New Patents
Merus’ First U.S. Patent Covering MCLA-117 and Merus’ Spleen to Screen® Technology for Efficient Generation of Biclonics® Candidates
Mar 06, 2018 07:00 am ET
Merus to Present at the Cowen & Co. 38th Annual Health Care Conference
UTRECHT, The Netherlands, March 06, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will present a company overview at the Cowen...
Feb 14, 2018 06:00 am ET
Merus Announces $55.8 Million Private Placement Offering of Common Stock
UTRECHT, The Netherlands, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that it has agreed to sell 3.1 million shares of its common shares to Biotechnology Value Fund,...
Feb 05, 2018 07:00 am ET
Merus Announces Participation in Four Investor Conferences in February 2018
UTRECHT, The Netherlands, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the Company’s management will participate at four upcoming investor conferences in February, including:
Jan 26, 2018 07:00 am ET
Merus Announces First Patient Dosed in a Phase 2 Clinical Trial of MCLA-128 in Two Metastatic Breast Cancer Patient Populations
Combination trial to evaluate MCLA-128 in HER2-positive and hormone receptor-positive/HER2-low metastatic breast cancer patients
Jan 08, 2018 07:00 am ET
Merus and Simcere Announce Strategic Collaboration on Multiple Bispecific Antibodies
UTRECHT, Netherlands and NANJING, China, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Merus (Nasdaq:MRUS) and Simcere Pharmaceutical Group today announced that Merus has agreed to grant Simcere an exclusive license to develop and commercialize in China three bispecific antibodies...
Jan 04, 2018 07:00 am ET
Merus Provides Clinical Updates for MCLA-117 and MCLA-158 Programs
- IND submitted to U.S. FDA for MCLA-117 in AML -
Jan 02, 2018 07:30 am ET
Merus to Present at the 36th Annual J.P. Morgan Healthcare Conference
UTRECHT, The Netherlands, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will present a company overview at the 36th Annual...
Dec 27, 2017 07:30 am ET
Merus Announces the U.S. Court of Appeals for the Federal Circuit Denies Regeneron's Petition to Rehear the Panel's Decision Affirming Merus' Inequitable Conduct Claim Against Regeneron
UTRECHT, The Netherlands, Dec. 27, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the United States Court of Appeals for the Federal Circuit denied Regeneron Pharmaceutical...
Nov 30, 2017 07:00 am ET
Merus Announces Third Quarter 2017 Financial Results and Clinical Highlights
UTRECHT, The Netherlands, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced financial results for the third quarter ended September 30, 2017 and provided a clinical update.
Nov 09, 2017 07:30 am ET
Merus to Present at the Jefferies London Healthcare Conference
UTRECHT, The Netherlands, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, CEO, will present at the Jefferies London Healthcare Conference on Thursday, November...
Oct 10, 2017 04:05 pm ET
Merus to Participate in the BIO Investor Forum
UTRECHT, The Netherlands, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will be participating in the 2017 BIO Investor Forum in a panel entitled, “Bispecific Antibodies to Supercharge Oncology Treatments” on Tuesday, October 17, 2017 from 8:30-9:25 a.m. PT.   ...
Sep 19, 2017 04:05 pm ET
Merus Announces Second Quarter 2017 Financial Results and Highlights Recent Progress
UTRECHT, The Netherlands, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced financial results for the second quarter ended June 30, 2017 and provided a corporate and clinical update....
Jul 11, 2017 04:05 pm ET
Merus Announces First Quarter 2017 Financial Results and Mid-Year Operating Results
Balance sheet strengthened with $120 million upfront payment and an $80 million share purchase from Incyte Corporation for global strategic research collaboration to discover and develop bispecific antibodies...
May 17, 2017 05:06 pm ET
Merus Announces Promising Results from MCLA-128 Phase 1/2 Study in Metastatic Breast Cancer
Results to be presented at the 2017 American Society of Clinical Oncology Annual Meeting...
May 03, 2017 04:05 pm ET
CORRECTING and REPLACING -- Merus Announces Fourth Quarter and Full Year 2016 Financial Results and Corporate Developments
In a release issued April 28, 2017 by Merus N.V. (Nasdaq:MRUS) with the same headline, an error was made such that the figures for the three months ended December 31, 2016 in the “Consolidated Statement of Profit or Loss and Comprehensive Loss” table were incorrect. The table has been updated, as have the corresponding numbers in the “Fourth Quarter 2016 Financial Results” section. The corrected release follows:...
Apr 28, 2017 04:47 pm ET
Merus Announces Fourth Quarter and Full Year 2016 Financial Results and Corporate Developments
UTRECHT, The Netherlands, April 28, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced financial results for the fourth quarter and full year ended December 31, 2016 and provided a corporate and clinical update....
Apr 20, 2017 04:05 pm ET
Merus Announces Data from a Phase 1/2 Study of MCLA-128 to be Presented at the 2017 American Society of Clinical Oncology Annual Meeting
UTRECHT, The Netherlands, April 20, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that data from a Phase 1/2 study of MCLA-128 for the treatment of metastatic breast cancer will be presented in a poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held on June 2-6, 2017 in Chicago, Illinois....
Mar 16, 2017 02:00 am ET
Merus Named BioCapital Europe 2017 Company of the Year
UTRECHT, The Netherlands, March 16, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that it has been named BioCapital Europe’s Company of the Year for 2017. In its 15th consecutive year, BioCapital Europe, organized by Life Sciences Partners (LSP), is Europe’s premier life sciences investment conference. The Company of the Year Award is given to the organization that has undergone the most substantial transformation in the previous year and has experienced a breakthrough with r...
Jan 23, 2017 04:05 pm ET
Merus Announces Closing of Global Strategic Research Collaboration with Incyte to Discover and Develop Bispecific Antibodies
UTRECHT, The Netherlands, Jan. 23, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced the closing of its global strategic research collaboration with Incyte Corporation (NASDAQ:INCY) focused on the research, discovery and development of bispecific antibodies utilizing Merus’ proprietary Biclonics® technology platform. The agreement grants Incyte the exclusive rights for up to eleven bispecific antibody research programs, including two of Merus’ current preclinical immuno-oncology...
Jan 05, 2017 07:44 am ET
Merus and the Institute for Research in Biomedicine (IRB) Barcelona Form Research Collaboration to Develop Bispecific Antibodies Targeting the Tumor Microenvironment
UTRECHT, The Netherlands, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, and the Institute for Research in Biomedicine (IRB) Barcelona, a research center devoted to understanding fundamental questions about human health and disease, today announced entry into a research collaboration to jointly develop novel agents that target the tumor microenvironment....
Nov 10, 2016 07:00 am ET
Merus to Present at the Jefferies London Healthcare Conference
UTRECHT, The Netherlands, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, CEO, will present at the Jefferies London Healthcare Conference on Thursday, November 17, 2016 at 11:20 PM GMT at the Waldorf Hilton in London, UK....
Oct 26, 2016 07:00 am ET
Merus Expands Executive Management Team with the Appointment of L. Andres Sirulnik, MD, PhD, as Chief Medical Officer
UTRECHT, The Netherlands, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced the appointment of L. Andres Sirulnik, MD, PhD, to the position of Chief Medical Officer, where he will be responsible for leading the Company's global clinical development strategy and clinical operations. Dr. Sirulnik will report to Ton Logtenberg, PhD, Chief Executive Officer of Merus, and will be based in the Company’s US Cambridge office....
Oct 19, 2016 07:00 am ET
Merus Receives Milestone Payment from Ono Pharmaceutical for Selection of Bispecific Antibody Candidate for Clinical Development and Extends Partnership with CMC Service Agreement
UTRECHT, The Netherlands, Oct. 19, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Company received an undisclosed milestone payment from Ono Pharmaceutical Co., LTD. (Osaka, Japan, ‘Ono’), under the ongoing collaboration between the two companies. The milestone was triggered as a result of pre-clinical confirmatory studies using the selected lead bispecific antibody candidate that Ono intends to advance into clinical testing. Ono and Merus have also extended their col...
Aug 31, 2016 07:00 am ET
Merus to Participate in Upcoming Investor Conferences
UTRECHT, The Netherlands, Aug. 31, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Company will participate in the following upcoming investor conferences:...
Aug 10, 2016 07:00 am ET
Merus to Present at the 2016 Wedbush PacGrow Healthcare Conference
UTRECHT, The Netherlands, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Company will present at the 2016 Wedbush PacGrow Healthcare Conference on Wednesday, August 17 at 2:30 PM ET at the Le Parker Meridien in New York City....
Aug 08, 2016 07:00 am ET
Merus Announces Second Quarter 2016 Financial Results and Reviews Recent Clinical Progress and Corporate Developments
UTRECHT, The Netherlands, Aug. 08, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced financial results for the second quarter ended June 30, 2016 and provided a review of recent accomplishments and clinical development plans....
Jul 12, 2016 07:00 am ET
Jun 01, 2016 07:00 am ET
Merus N.V. Signs Commercial Multi-Product License for ProBioGen’s GlymaxX® ADCC Enhancement Technology
BERLIN & UTRECHT, The Netherlands, June 01, 2016 (GLOBE NEWSWIRE) -- ProBioGen AG and Merus N.V. (Nasdaq:MRUS) today jointly announced that Merus has signed a commercial multi-product license agreement for ProBioGen’s GlymaxX® ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity) enhancement technology. Under the terms of the agreement, Merus has obtained non-exclusive use of GlymaxX® technology for Merus’ Biclonics® pipeline of bispecific cancer antibodies to enhance their ADCC activity. Financial details of the license agreement were not disclosed....
May 31, 2016 07:00 am ET
Merus N.V. Announces Closing of Partial Exercise of Underwriters' Over-Allotment Option
UTRECHT, the Netherlands, May 31, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (“Merus”) (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced the closing of a partial exercise of the over-allotment option by the underwriters of its previously announced initial public offering in the amount of an additional 639,926 common shares at the initial public offering price of $10.00 per share. The sale of the additional shares closed on May 26, 2016, bringing the total number of common shares sold by Merus in its initial public offerin...
May 24, 2016 02:16 pm ET
Merus N.V. Announces Closing of Initial Public Offering
UTRECHT, the Netherlands, May 24, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (“Merus”) (Nasdaq:MRUS) today announced the closing of its initial public offering of 5,500,000 common shares at an initial public offering price of $10.00 per share.  The shares began trading on The NASDAQ Global Market under the ticker symbol “MRUS” on May 19, 2016. All of the common shares in the offering were offered by Merus.  The net proceeds to Merus from the sale of shares in the offering are estimated to be approximately $47.3 million, after deducting the underwriting discounts and commissions and estimated offe...
May 19, 2016 06:00 am ET
May 18, 2016 08:49 pm ET
Merus Announces Pricing of Initial Public Offering
UTRECHT, the Netherlands, May 18, 2016 (GLOBE NEWSWIRE) -- Merus B.V. (“Merus”) today announced the pricing of its initial public offering of 5,500,000 common shares at an initial public offering price of $10.00 per share, before underwriting discounts and commissions. All of the common shares are being offered by Merus. In addition, Merus granted the underwriters a 30-day option to purchase up to an additional 825,000 common shares at the initial public offering price.  The shares are expected to begin trading on The NASDAQ Global Market on May 19, 2016 under the ticker symbol “MRUS.”...